The Estonian Biobank cohort is a volunteer-based sample of the Estonian resident adult population (aged 18 years). The current number of participants-close to 52000--represents a large proportion, 5%, of the Estonian adult population, making it ideally suited to population-based studies. General practitioners (GPs) and medical personnel in the special recruitment offices have recruited participants throughout the country. At baseline, the GPs performed a standardized health examination of the participants, who also donated blood samples for DNA, white blood cells and plasma tests and filled out a 16-module questionnaire on health-related topics such as lifestyle, diet and clinical diagnoses described in WHO ICD-10. A significant part of the cohort has whole genome sequencing (100), genome-wide single nucleotide polymorphism (SNP) array data (20 000) and/or NMR metabolome data (11 000) available (http://www.geenivaramu.ee/ for-scientists/data-release/). The data are continuously updated through periodical linking to national electronic databases and registries. A part of the cohort has been recontacted for follow-up purposes and resampling, and targeted invitations are possible for specific purposes, for example people with a specific diagnosis. The Estonian Genome Center of the University of Tartu is actively collaborating with many universities, research institutes and consortia and encourages fellow scientists worldwide to co-initiate new academic or industrial joint projects with us.
Why was the Biobank initiated?
The Estonian Genome Project Foundation initiated the Estonian Biobank Project in 1999, which was transformed into the Estonian Genome Center of the University of Tartu (EGCUT) in 2007.
1, 2 The objective was to investigate the genetic, environmental and behavioural background of common diseases and traits by creating a biobank with biological samples and health records from a large proportion of the population. Since 2012, the biobank has been sited in a new building specifically designed for the EGCUT and biobanking purposes in Tartu, Estonia.
To enable the establishment and ensure the legal basis for the Estonian Biobank, the Estonian Human Genes Research Act (HGRA) 3 was passed by the Parliament of Estonia in 2000. According to this law, the EGCUT has the right to use and store personal data and biological samples for three purposes:
i. to promote the development of genetic research; ii. to collect information on the health status of the Estonian population combined with genetic information; iii. to use the results of genetic research to improve public health.
Investigating the population's health and '-omics' data will be accomplished through a longitudinal populationbased cohort study of a large variety of samples with extensive clinical information. The information is continuously updated through follow-up on health status using both electronic population registries and re-examinations of the participants.
About €12 million from both the private and public sectors has been spent between 2000 and 2013 to establish the Estonian Biobank with the health records, DNA, plasma and white blood cell (WBC) samples from 52 000 participants. Since 2007, the core funding for the Estonian Biobank at the EGCUT is provided by the Estonian Government through the budgets of the Ministry of Social Affairs, the Ministry of Economics and Communications and the Ministry of Education and Research. The financing of the EGCUT and the Estonian Biobank is regulated through the HGRA. Funding for the research projects is competitively based. About €10 million has been received for infrastructure development and research projects.
Who is in the cohort?
The Estonian Biobank has reached a cohort size of 52 000 participants aged 18 years and older. 4 The age, sex and geographical distribution closely reflect those of the Estonian adult population (see Figures 1 and 2 ) and encompass close to 5% of the entire adult population of Estonia, 5 making the Estonian Biobank internationally competitive in terms of the absolute number of participants as well as the relative number of participants as a proportion of the entire population-all being characterized according to the same protocol. When comparing the numbers of women and of men in the EGCUT database with those in the Estonian population, one can observe that as in most other voluntary population-based studies, females participate more actively than males ( Figure 1 ). [6] [7] [8] There are proportionally fewer males in almost all age groups except for the group aged 18-21 years; women are represented in large numbers in all age groups up to 60 years. Overall, the representation of men in the biobank is 3.4% and of women is 5.5% of the adult population of Estonia, and the representation of men and women in the biobank is 34% and 66%, respectively, compared with 45% and 55%, respectively, in the general population. Older people tend to participate less frequently; however, all age groups are well represented.
The gaps in our population caused by the Second World War, for instance, are reflected by the gaps observed in the age groups of 62-66 and 40-44 years.
What has been measured and collected?
For the recruitment of participants and for the collection of samples and health data, a unique network of data collectors was set up consisting of GPs and other medical personnel in private practices and hospitals or in the recruitment offices of the EGCUT (Figure 2 samples collected has grown in the past 12 years (Table 1) . The latest version of the questionnaire ( Figure S1 , available as Supplementary data at IJE online) consists of approximately 330 questions with more than 1000 data fields. 4 To ensure standardized and accurate data collection procedures, a computer-assisted personal interview (CAPI) was used. The software allows the recruiter to fill out the questionnaire together with the participant. The questions were asked in a specific order with a slight variation depending on the age, gender and reported diagnoses of the participant. When obligatory fields were not properly filled in, the recruiter was notified.
The involvement of GPs as recruiters for the EGCUT has provided several advantages in terms of health data collection. Due to the developments in the Estonian information technology infrastructure, there are electronic health records available for GPs that include pre-existing medical data for the patients. Permitted by the HGRA, this pre-existing medical information is included in the EGCUT phenotypic data of the participants. The GPs also recorded whether the diagnoses were confirmed by a clinician orgeneral practitioner or were self-reported (Table 2 ). This provides confidence in the reliability of the diagnosis.
For all starting data collectors, the first 10 questionnaires were monitored for completeness and illogical answers, and thereafter 10% of all the questionnaires were selected randomly for monitoring; 21% of the questionnaires have been inspected and corrected when necessary. From the monitored questionnaires, 99% were classified as of high quality, meaning that all the fields were filled in and the answers appeared logical.
The collected samples were transported to the central laboratory of the EGCUT within 24-48 h and every step was recorded with a time stamp. Upon arrival at the central laboratory, the samples were assigned a new 16-digit code by the coding centre to maintain the anonymity of the donors, and each tissue sample was barcode-labelled. The coding centre is a secured area where all phenotype and genealogy data and the keys between the codes for the different information systems are stored in a highly secure environment. The server in the coding centre is not connected to the internet. Data are transferred by USB memory devices. Four separate codes are implemented: a biological sample and data transport code; a unique participant ID; a laboratory code for the biological sample; and a unique release code for data release for further research projects. All data transfers and databases are encrypted.
The DNA, plasma and WBCs are isolated immediately, packaged into CryoBioSystem high security straws (DNA in 10-14, plasma in 7, WBCs in 2 straws) and stored in liquid nitrogen. NEO-PI-R, Neuroticism-Extraversion-Openness Personality Inventory Revised. 15 and control. The completed questionnaires were sent to the EGCUT electronically as an encrypted document, and the consent forms were the only documents that were stored in the coding centre in paper form. The questionnaire, freely available online, includes personal, genealogical, lifestyle, educational and occupational history questions (Table 3, Supplementary Tables S1 and  S2, available Altogether there are currently over 377 000 diagnoses for 52 000 participants with approximately 7.4 diagnoses on average per participant (Table S1, available as Supplementary data at IJE online). The common diseases are proportionally adequately represented. 21 For example, among the EGCUT participants there are 21 800 individuals with a total of 40 200 diagnoses of the circulatory system. Similarly, there are 7500 participants with 8900 diagnoses of neoplasm in the EGCUT database. Additionally, there are 30 700 participants with 60 800 diagnoses of the respiratory system and 9900 participants with 12 700 diagnoses of endocrine, nutritional and metabolic diseases (Table S1 , available as Supplementary data at IJE online).
How often have the participants been followed up?
The usefulness of a cohort for research purposes is dependent on the information accompanying the biological samples. The scientific value will decrease unless the collection of information is maintained, constantly updated and, when possible, expanded. The HGRA addresses this issue The class of reliability of the diagnosis has not been specified.
by permitting the EGCUT to re-contact the participants for follow-up purposes or for collection of additional information not otherwise available. The follow-up data allow scientists to conduct longitudinal studies, making it possible to provide comparisons of epigenomic, metabolomic and phenotypic profiles before and after the onset of a disease.
There have been two projects to re-contact for followup purposes. In 2008, a sample of 822 participants, in an age range of 20-74 years, was selected to be re-contacted to validate the initial questionnaire data, as well as to study the dynamics in various phenotypic characteristics and in biological measurements. Re-contacting participants was carried out between 2008 and 2010, with a response rate of 57.2%. A second wave of re-contacting for follow-up purposes started in 2011 and 1072 participants visited our recruitment centres in Tallinn and Tartu for the second time, with a response rate of 41.1%. The difference in response rate could be accounted for different methods of recontacting. Whereas the first time the participants were contacted through their GP, the second time they were contacted directly by mail. Although the Estonian Biobank updates the participants' home addresses through the Population Register, 22 , the addresses in the register do not always correspond to the actual residency of the participant. Hence it is not possible to state the response rate among those who received the invitation.
The HGRA permits the enrichment of phenotypic data by updating the health data from medical records available in national health databases and hospital registries. Linking to registries is conducted semi-annually. So far, the EGCUT has successfully augmented data using the Estonian Population Register, the Estonian Causes of Death Registry, the Estonian Cancer Registry and the Estonian Tuberculosis Registry (Table 4) . 23 
What has been found? Key findings and publications
The EGCUT is collaborating scientifically on both national and international levels. One of the first studies established Estonians as a representative population for northern The EGCUT participates in many phenotype-driven and genetic epidemiological consortia such as GIANT (Genetic Investigation of ANthropometric Traits), CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology), ENGAGE (European Network for Genetic and Genomic Epidemiology), DIAGRAM (DIAbetes Genetics Replication And Meta-analysis), MAGIC (Meta-Analyses of Glucose and Insulin-related traits), CARDIOGRAM (Coronary ARtery DIsease Genome-wide Replication And Metaanalysis) and MAGENETIC (Metabolites And GeNETIcs Consortium). In total, the EGCUT cohort is currently involved in more than 100 international projects. The majority of the collaborators are universities with their own biobank collections, or technology providers such as BGI in Shenzhen, China, and Illumina Inc. from San Diego, CA, USA. The EGCUT participates in several European Union-funded projects such as Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) 28 and
BBMRI-Large Prospective Cohorts (BBMRI-LPC)
. 29 Being one of the founding members of the Public Population Project in Genomics (P 3 G), 30 the EGCUT also takes part in this global organization. Due to the EGCUT participation in these consortia, a wide spectrum of '-omics' data are available for a significant part of the cohort (Table 5) .
Altogether, a wide range of phenotypes have been investigated, with over 200 traits and sub-phenotypes under analysis: these include anthropometric and blood biochemistry traits, [34] [35] [36] [37] [38] [39] [40] common and rare diseases, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] personality and lifestyle, [55] [56] [57] [58] [59] [60] [61] [62] and molecular phenotypes [63] [64] [65] [66] [67] [68] [69] [70] to highlight some of the scientific findings. One of the motivations of the EGCUT is to investigate these phenotypes to better understand the pathophysiological mechanisms leading to disease onset and come up with biomarkers with better prediction power and accuracy. Such studies would eventually allow moving the paradigm of general healthcare from curing (dealing with disease outcomes) to prevention (changing the lifestyle or preventive drug treatment). The complete list of publications can be found at http:// www.geenivaramu.ee/for-scientists/publications.html.
What are the main strengths and weaknesses?
The main strength of the Estonian Biobank is that it is a population-based biobank with a longitudinal and prospective database. This means that a wide range of age groups and phenotypes are represented. Whereas usually there is a tendency for urban populations to be overrepresented, this is not the case for the Estonian Biobank cohort (Figure 2) .
One of the important strengths is that the biobank has available DNA, plasma and WBCs for each donor. This means that it is possible to analyse the direct effects of sequence variants on metabolism. Even more, it is possible to transform the cells into cell lines or induced pluripotent stem (iPS) cells and directly carry out molecular biology or genetics experiments.
Another strength is provided by the HGRA together with the broad consent form that allows participation in a wide range of research projects without having to re-contact and ask for re-consent. 3, 71 The HGRA and consent form also permit donors to request the release of their genetic data, hereditary characteristics and genetic risks obtained from genetic research conducted. This would eventually enable the conduct of projects on personal genome testing, risk perception and management in industrial settings.
Additionally, the HGRA allows the Biobank to obtain additional information through linkage of records with the national electronic registries and major hospitals. All the registries are centrally linked through a nationwide technical infrastructure, the so-called X-road, allowing secure data exchange between databases,and the uniform identifiers of individuals enable quick and errorless linking. 72 The HGRA also imposed restrictions on the activities of the EGCUT and the data collected in the Estonian Biobank. Participation had to be entirely voluntary-only the individuals interested in joining the Estonian Biobank, after hearing about it either at special promotion events, from the media, from friends or at the family physician's office or hospitals, are recruited. The EGCUT was not allowed to send the invitation letters to their home addresses. 3, 4 Therefore, the biobank does not represent a classical random sample and could be subject to recruitment bias. A considerable proportion of the population recruited, however, could compensate for this bias. Hence, although not classically random, the cohort can still be considered representative of the population.
Although recruitment was open to everyone, there is a disproportion of ethnic Estonians and ethnic Russians in the biobank, with Estonians being overrepresented (81% in the biobank compared with the 70% in the general population) and Russians underrepresented (16%in the biobank compared with the 25% in the general population).
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Another weakness is the limited depth of some subquestionnaires. For instance, a relatively brief food frequency questionnaire was administered with no detailed information on energy or nutrient intake; measurements of fasting glycaemic blood traits such as insulin level are available only for a limited set of samples. The limited depth of collected data can sometimes limit the number of projects in which the data can be used. However, more extensive questionnaires would have required even longer interview times and would have cost much more, possibly resulting in a smaller cohort size.
Can I get access to the data? Where can I find out more?
The EGCUT shares anonymous health, lifestyle, demographic and genetic data as well as biological materials (DNA, WBCs and plasma) for research and development projects. The data sharing is conducted in accordance with the regulations of the HGRA. A data application form can be found at www.biobank.ee. 4 The research project has to obtain approval from the Ethics Review Committee on Human Research of the University of Tartu 74 as well as approval from the EGCUT scientific committee. 33 The EGCUT has a policy for data sharing, which implies that for the EGCUT to share its resources, the applicant has to send the scientific results obtained from the research project conducted using the data or samples of the gene donors back to the Estonian Biobank. 3 These results will be added to the EGCUT database.
Future directions and development
The EGCUT has now established a compact biobank of considerable size. In the future, the emphasis will shift to studying the underlying mechanisms of common complex diseases. Another goal is informational enrichment through the additional collection of '-omics' data as well as phenotypic data. Concurrent with the data enrichment and research efforts, the EGCUT is working on building a system for implementing the information into the Estonian healthcare system. This is a complex process and requires multidisciplinary involvement from the medical, legal and research fields. As the first step, the genomes of 5000 gene donors will be sequenced in order to describe rare sequence variants and haplotypes among Estonians, and use them for the design of a new genotyping microarray, which can be added as supplemental markers in addition to common genome-wide and more rare exonic variants. Finally, this array will be used to genotype all gene donors in the Estonian Biobank and, when successful, everybody in Estonia aged between 35 and 65 years will be offered the test. With automated diagnosis support and risk estimation software incorporated into the eHealth system, we hope to provide disease risks and medication response information directly to the healthcare providers and thereby introduce genomics into healthcare in Estonia.
Supplementary data
Supplementary data are available at IJE online.
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